Nirmatrelvir-ritonavir: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
* eGFR 30-59 mL/min: nirmetrelvir/ritonavir 150 mg/100 mg p.o. bid |
* eGFR 30-59 mL/min: nirmetrelvir/ritonavir 150 mg/100 mg p.o. bid |
||
* eGFR <30 mL/min: not recommended |
* eGFR <30 mL/min: not recommended |
||
| + | |||
| + | === Hepatic Dosing === |
||
| + | |||
| + | * [[Child-Pugh classification|Child-Pugh]] class C: contraindicated |
||
[[Category:Medications]] |
[[Category:Medications]] |
||
Revision as of 13:54, 9 March 2022
Dosing
- COVID-19: Nirmatrelvir/ritonavir 300 mg/100 mg p.o. bid for 5 days, started within 5 days of symptom onset
Renal Dosing
- eGFR ≥60 mL/min: no adjustment
- eGFR 30-59 mL/min: nirmetrelvir/ritonavir 150 mg/100 mg p.o. bid
- eGFR <30 mL/min: not recommended
Hepatic Dosing
- Child-Pugh class C: contraindicated
